Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Merck & Co., Inc. is a health care company ... animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Merck, a leading science and technology company, today launched a beta version of M-Trust, a secure cyber-physical trust ...

Today's Research Daily features a real-time update on the Q4 earnings season and fresh Chevron (CVX), Merck (MRK), QUALCOMM ...

BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...